Hemab Therapeutics (NASDAQ:COAG) Posts Earnings Results

Hemab Therapeutics (NASDAQ:COAG) issued its quarterly earnings data on Thursday. The company reported ($23.98) earnings per share for the quarter, Zacks reports.

Hemab Therapeutics Stock Down 0.6%

Shares of NASDAQ:COAG opened at $26.30 on Friday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $36.61.

Insider Activity at Hemab Therapeutics

In other Hemab Therapeutics news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was purchased at an average price of $18.00 per share, with a total value of $48,150,000.00. Following the acquisition, the director owned 6,149,096 shares in the company, valued at approximately $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have bought 2,902,872 shares of company stock valued at $53,769,784.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.